CDR1 Gene

CDR1 — Cerebellar Degeneration-Related Protein 1 (CDR1AS)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CDR1AS</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CDR1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Cerebellar Degeneration-Related Protein 1</td></tr>
<tr><td><strong>Gene Type</strong></td><td>Circular RNA (circRNA)</td></tr>
<tr><td><strong>Chromosome</strong></td><td>Xq27.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[64506](https://www.ncbi.nlm.nih.gov/gene/64506)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000283757</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>Q9UIU7</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>

Overview

CDR1 — Cerebellar Degeneration-Related Protein 1 (CDR1AS)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CDR1AS</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CDR1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Cerebellar Degeneration-Related Protein 1</td></tr>
<tr><td><strong>Gene Type</strong></td><td>Circular RNA (circRNA)</td></tr>
<tr><td><strong>Chromosome</strong></td><td>Xq27.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[64506](https://www.ncbi.nlm.nih.gov/gene/64506)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000283757</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>Q9UIU7</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>

Overview

CDR1, more commonly known by its circular RNA form CDR1AS, represents one of the most extensively studied circular RNAs in the context of neurodegenerative diseases. Unlike conventional linear messenger RNAs, CDR1AS is a stable circular RNA molecule that lacks the 5' cap and 3' polyadenylated tail typical of most coding transcripts. This circular structure confers remarkable stability, allowing CDR1AS to persist in cells for days to weeks compared to the hours that typical mRNAs remain before degradation. Originally identified as a cerebellar degeneration-related antigen in paraneoplastic cerebellar degeneration patients, CDR1AS has emerged as a critical regulator of microRNA activity in the brain, with profound implications for Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions.

The fundamental mechanism through which CDR1AS exerts its biological effects is through microRNA sponging—a process by which circRNAs bind to specific microRNAs and sequester them, thereby modulating the expression of target genes that would otherwise be repressed by those microRNAs.[@hansen2013] CDR1AS contains over 70 binding sites for microRNA-7 (miR-7), making it one of the most potent miRNA sponges identified to date.[@shi2019] MiR-7 is itself a regulator of numerous genes implicated in neurodegeneration, including BACE1 (beta-site amyloid precursor protein cleaving enzyme 1), SNCA (alpha-synuclein), and UCHL1 (ubiquitin carboxy-terminal hydrolase L1). Through this sponging activity, CDR1AS indirectly influences amyloid processing, alpha-synuclein expression, and protein degradation pathways central to neurodegenerative disease pathogenesis.

The discovery and characterization of CDR1AS has fundamentally altered our understanding of RNA biology and created new paradigms for understanding gene regulation in the nervous system. Circular RNAs, once dismissed as transcriptional noise or splicing artifacts, are now recognized as important functional molecules with critical roles in development, homeostasis, and disease. CDR1AS stands as the archetypal example of how these molecules can participate in disease mechanisms and potentially serve as therapeutic targets or biomarkers.[@yang2018]

Molecular Biology and Structure

The CDR1 gene is located on the X chromosome at position Xq27.1 and produces a circular RNA transcript through a process known as back-splicing. Unlike canonical splicing that joins adjacent exons in a linear fashion, back-splicing connects a downstream splice donor to an upstream splice acceptor, creating a covalently closed circular structure. This transcript does not encode a protein in the traditional sense—rather, CDR1AS functions primarily as a non-coding RNA that exerts its effects through RNA-RNA interactions rather than protein production.

The CDR1AS circular RNA is approximately 1.5 kilobases in length and contains multiple miR-7 binding sites distributed throughout its sequence. Each miR-7 binding site consists of an 8-nucleotide "seed region" complementary sequence that pairs with miR-7, the critical region for microRNA targeting. The presence of over 70 such sites creates an extremely high-affinity sponge capable of effectively sequestering miR-7 molecules and preventing them from interacting with their other target mRNAs. This sequestration is not equivalent to degradation—CDR1AS binds and releases miR-7 in a regulated manner, allowing for dynamic control of miR-7 activity.

The biogenesis of CDR1AS and other circular RNAs involves the spliceosome machinery and is often mediated by complementary sequences in the flanking introns that bring the splice sites into proximity. For CDR1AS, the flanking introns contain inverted repeat sequences that can form double-stranded RNA structures, facilitating the back-splicing event. Various RNA-binding proteins including Quaking (QKI), Muscleblind (MBNL1), and Sam68 have been implicated in regulating circular RNA formation, though the specific regulators of CDR1AS biogenesis in neuronal cells remain an active area of investigation.

CDR1AS expression is subject to transcriptional regulation by multiple transcription factors. The promoter region contains binding sites for neuronal transcription factors including Ngn2 and NeuroD1, explaining its neuron-specific expression pattern. Epigenetic modifications, including DNA methylation and histone modifications, also influence CDR1AS expression, with some evidence suggesting that epigenetic dysregulation contributes to altered CDR1AS levels in neurodegenerative disease states.

Function as a microRNA Sponge

The primary biological function of CDR1AS is to act as a molecular sponge for miR-7 and, to lesser extents, other microRNAs including miR-1290 and miR-153. MiR-7 is a brain-enriched microRNA with critical roles in neuronal development, synaptic plasticity, and the regulation of genes implicated in neurodegenerative diseases. Under normal conditions, miR-7 binds to the 3' untranslated regions (UTRs) of target mRNAs and recruits the RNA-induced silencing complex (RISC), leading to mRNA degradation or translational repression.

By sequestering miR-7, CDR1AS prevents this repression and allows target gene expression to proceed. The consequences of CDR1AS activity are therefore indirect—the effects depend on which miR-7 targets are relevant in a given cellular context. In neurons, key miR-7 targets include:

• BACE1: The β-secretase enzyme that cleaves amyloid precursor protein (APP) to produce amyloid-beta peptides. Increased BACE1 activity promotes amyloid production, a hallmark of AD pathogenesis.
• SNCA: α-Synuclein, the protein that forms Lewy bodies in PD. Proper regulation of SNCA expression is critical, as overexpression can lead to aggregation and toxicity.
• UCHL1: Ubiquitin carboxy-terminal hydrolase L1, an enzyme important for protein degradation. Loss of UCHL1 function contributes to protein aggregation.
• RE1 Silencing Transcription Factor (REST): A neuronal transcription factor that regulates gene expression during stress. REST dysregulation has been implicated in AD.

Expression in the Brain

CDR1AS exhibits a distinctive expression pattern in the nervous system, with highest levels in brain tissue and particularly in neuronal populations. In the human brain, CDR1AS is enriched in the cerebral cortex, hippocampus, cerebellum, and substantia nigra—regions prominently affected in neurodegenerative diseases. This regional distribution correlates with the vulnerability of these areas to pathology in AD and PD.

Within the brain, CDR1AS shows specific cellular localization. It is highly expressed in neurons where it localizes to both the cell body and neuronal processes, including dendrites and axons. Synaptic fractions are particularly enriched for CDR1AS, suggesting important functions at synapses. At synapses, CDR1AS may regulate local miR-7 activity, influencing the expression of synaptic proteins and modulating synaptic plasticity. This synaptic localization implicates CDR1AS in learning, memory, and other cognitive functions that depend on synaptic remodeling.

Expression analysis across development reveals that CDR1AS levels increase during embryonic development and remain high throughout adulthood. This temporal pattern suggests important functions in both brain development and maintenance of neuronal homeostasis. Some studies indicate that CDR1AS expression can be modulated by neuronal activity—depolarization or synaptic activation can alter CDR1AS levels, providing a mechanism by which experience-dependent processes might influence this regulatory axis.

Astrocytes and other glial cells express lower levels of CDR1AS compared to neurons, though some expression has been detected. The functional significance of glial CDR1AS is less well characterized but may relate to glial-neuronal communication or responses to neural injury.

Alzheimer's Disease

CDR1AS has emerged as a significant player in Alzheimer's disease pathogenesis through its regulation of miR-7 and downstream targets. Multiple studies have documented altered CDR1AS expression in AD brain tissue, with most reports indicating reduced CDR1AS levels compared to age-matched controls. This reduction could have several consequences for AD pathogenesis.

The decreased CDR1AS in AD would be expected to increase free miR-7 activity, enhancing the repression of miR-7 target genes. BACE1, one of the most important miR-7 targets, would experience increased repression under normal circumstances—but paradoxically, BACE1 expression and activity are elevated in AD. This apparent contradiction suggests that other regulatory mechanisms override miR-7-mediated repression in AD, or that the relationship between CDR1AS, miR-7, and BACE1 is more complex than initially appreciated. Some studies suggest that while CDR1AS decreases, the miR-7/BACE1 axis may be uncoupled in AD, allowing BACE1 upregulation despite increased miR-7 activity.

The SNCA target is particularly relevant for understanding CDR1AS's role in AD. While classically associated with PD, α-synuclein aggregation also occurs in a significant subset of AD cases, and cross-talk between amyloid and α-synuclein pathologies has been documented. By regulating SNCA expression through miR-7 sponging, CDR1AS may influence the development of Lewy body pathology in AD patients.

Additional AD-relevant effects of CDR1AS dysregulation include modulation of tau pathology through UCHL1 and other targets, synaptic dysfunction through regulation of synaptic protein expression, and neuronal stress responses through REST and other transcription factors. The overall impact of CDR1AS loss in AD is to create a permissive environment for multiple aspects of neurodegeneration.

Therapeutic strategies targeting CDR1AS in AD are under investigation. Overexpression of CDR1AS through viral vector delivery could potentially restore miR-7 sequestration and normalize downstream pathways, though this approach would need careful validation given the complexity of the regulatory network. Alternatively, direct miR-7 inhibitors or mimics might achieve similar effects. Biomarker applications—using CDR1AS levels in cerebrospinal fluid or blood as indicators of disease state or progression—are also being explored.

Parkinson's Disease

In Parkinson's disease, CDR1AS plays a particularly prominent role through its regulation of α-synuclein expression. SNCA is one of the most strongly validated miR-7 targets, and CDR1AS directly modulates SNCA levels through miR-7 sequestration. This regulatory axis provides a mechanistic link between CDR1AS and PD pathogenesis.

Post-mortem studies of PD brain tissue have revealed altered CDR1AS expression in the substantia nigra and other affected regions. Some studies report increased CDR1AS, potentially representing a compensatory response to limit α-synuclein expression. Others have found decreased CDR1AS, suggesting that reduced sponging allows increased miR-7 activity that might have additional pathogenic consequences. The direction of change may depend on disease stage, individual variability, or methodological differences between studies.

The importance of the CDR1AS-miR-7-SNCA axis in PD is supported by experimental models. Overexpression of CDR1AS in cellular and animal models reduces α-synuclein expression and attenuates α-synuclein-induced toxicity. Conversely, CDR1AS knockdown or miR-7 overexpression exacerbates α-synuclein pathology. These findings suggest that enhancing CDR1AS activity might have therapeutic benefit in PD.

Beyond α-synuclein regulation, CDR1AS influences other PD-relevant pathways. MiR-7 targets include genes involved in mitochondrial function (such as PINK1 and PARKIN, though the relationships are complex), oxidative stress responses, and neuroinflammation. Through these targets, CDR1AS dysregulation may contribute to multiple aspects of PD pathogenesis beyond α-synuclein aggregation.

Dysregulated CDR1AS may also interact with other PD genes. GBA (glucocerebrosidase) mutations are the most common genetic risk factor for PD, and some evidence suggests that GBA deficiency affects microRNA regulatory pathways. The intersection between GBA biology and CDR1AS function represents an area requiring further investigation.

Neurodevelopmental Functions

Beyond disease associations, CDR1AS has important functions in normal brain development and neuronal physiology. During development, CDR1AS expression is high and regulated in spatial and temporal patterns that suggest stage-specific roles. Studies in model systems have demonstrated that CDR1AS influences neurogenesis, neurite outgrowth, and synaptic formation—processes essential for constructing functional neural circuits.

In neuronal differentiation, CDR1AS levels increase as neurons mature, and experimental manipulation of CDR1AS affects the differentiation trajectory. Overexpression promotes neuronal differentiation while knockdown impairs it, suggesting that CDR1AS contributes to the molecular programs that drive neurons from progenitors to fully differentiated cells. These effects are mediated through miR-7 regulation of target genes involved in neurodevelopmental processes.

At synapses, CDR1AS's enrichment suggests functions in synaptic development and plasticity. Studies have demonstrated that CDR1AS localizes to synaptosomes and can regulate synaptic protein expression through miR-7 sponging. Synaptic activity can modulate CDR1AS levels, creating a feedback loop between neuronal activity and this regulatory axis. Synaptic plasticity mechanisms underlying learning and memory may therefore involve CDR1AS, and dysregulation could contribute to the synaptic failure that characterizes neurodegenerative diseases.

Therapeutic Implications

The identification of CDR1AS as a disease-relevant regulatory RNA has opened therapeutic opportunities that were previously unavailable. Several strategies are being pursued to target the CDR1AS-miR-7 axis:

CDR1AS Overexpression: Delivering CDR1AS to affected brain regions using viral vectors (AAV, lentivirus) could enhance miR-7 sequestration and normalize downstream pathways. This approach has shown promise in preclinical models of PD and AD, where CDR1AS overexpression reduces α-synuclein and BACE1 expression, respectively. Challenges include achieving adequate brain penetration, achieving cell-type specificity, and avoiding off-target effects.

miR-7 Modulation: Direct administration of miR-7 inhibitors (antagomirs) or mimics could manipulate the downstream pathway. miR-7 inhibitors would be appropriate if CDR1AS loss leads to excessive miR-7 activity, while miR-7 mimics might be useful if the relationship is reversed. The relative simplicity of these approaches is attractive, though achieving brain delivery remains challenging.

Small Molecule Modulators: Identification of compounds that enhance or inhibit CDR1AS expression or activity would provide pharmacological approaches to therapy. Screening for drugs that increase CDR1AS levels or stabilize the CDR1AS-miR-7 interaction could yield novel therapeutics.

Biomarkers: CDR1AS can be detected in cerebrospinal fluid and blood, where levels may correlate with disease state or progression. As a biomarker, CDR1AS could assist in diagnosis, monitor therapeutic response, or provide prognostic information. The stability of circular RNAs makes them attractive as biomarkers compared to more labile RNA species.

Relationship to Other Circular RNAs

CDR1AS belongs to a larger family of circular RNAs that are abundant in the brain. Other well-characterized neuronal circRNAs include circSAMD10, circSTAU2, and circHLIP, each with distinct targets and functions. The field of circular RNA biology has expanded rapidly, with thousands of circRNAs now documented in the human transcriptome. Many of these circular RNAs exhibit tissue-specific expression and are dysregulated in disease states.

Comparing CDR1AS to other circular RNAs reveals both common themes and unique features. The density of miR-7 binding sites in CDR1AS is extraordinary compared to most other circRNAs, making it an unusually potent miRNA sponge. However, the principle—circular RNAs sequestering microRNAs to modulate gene expression—is shared broadly. Some circRNAs function in other ways, acting as scaffolds for protein complexes or templates for translation.

Understanding the broader circRNA landscape in neurodegenerative diseases may reveal additional therapeutic targets and biomarkers. The coordinated regulation of multiple circRNAs suggests that fundamental biogenesis pathways might be targets for intervention.

Key Publications

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease) — AD disease page
• [Parkinson's Disease](/diseases/parkinsons-disease) — PD disease page
• [alpha-Synuclein](/proteins/alpha-synuclein) — SNCA protein
• [BACE1](/proteins/bace1-protein) — Beta-secretase enzyme
• [Circular RNAs in Neurodegeneration](/mechanisms/circular-rnas-neurodegeneration) — circRNA mechanisms
• [MicroRNA Regulation](/mechanisms/microrna-regulation-neurodegeneration) — miRNA pathways

External Links

• [NCBI Gene: 64506](https://www.ncbi.nlm.nih.gov/gene/64506) — Gene database entry
• [Ensembl: ENSG00000283757](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000283757) — Genome browser
• [UniProt: Q9UIU7](https://www.uniprot.org/uniprot/Q9UIU7) — Protein information
• [CircAtlas](http://circatlas.biols.ac.cn/) — Circular RNA database
• [miRBase](http://www.mirbase.org/) — microRNA database

References